09/14/23 9:25 AMNasdaq : ALLR clinical triallow floatAllarity Therapeutics Gaining Momentum? Hits Multiple Milestones Including Positive Publications In PLOS One And At ASCO, Positive Early Data From An Ongoing Clinical Trial, And External Partnering For Its DRP(R) TechnologyCAMBRIDGE, MA / ACCESSWIRE / September 14, 2023 / Allarity Therapeutics (NASDAQ:ALLR) is a biotechnology company focused on realizing true personalized cancer care by developing targeted cancer therapies coupled with companion diagnostics. The company's unique approach involves utilizing itsRHEA-AIpositive
08/30/23 4:05 PMNasdaq : ALLR low floatPLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib- T he DRP ® -Dovitinib companion diagnostic demonstrated an ability to identify advanced renal cell carcinoma patients that have improved clinical benefit from dovitinib treatment , as compared to unselected patients BOSTON (August 30, 2023) — Allarity Therapeutics, Inc. (Allarity or the Company)RHEA-AIneutral
07/31/23 6:00 AMNasdaq : ALLR clinical triallow floatAllarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion DiagnosticsBOSTON and SYDNEY (July 31, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP ® companion diagnostics for personalized cancer care, and Detsamma Investments Pty. Ltd.RHEA-AIneutral
07/24/23 6:00 AMNasdaq : ALLR managementlow floatAllarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology ExecutivesNew appointments bring therapeutic development expertise and proven leadership to support continu ed progress of Allarity’s mult i ple oncology clinical programs BOSTON (July 24, 2023) — Allarity Therapeutics, Inc. (Allarity or the Company), a clinical-stage pharmaceutical company developing novelRHEA-AIneutral
07/06/23 6:00 AMNasdaq : ALLR offeringlow floatAllarity Therapeutics, Inc. Announces Pricing of $11 Million Public OfferingBOSTON, MA (July 6, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced the pricing ofRHEA-AIneutral
07/05/23 9:45 AMNasdaq : ALLR clinical triallow floatInitial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer PatientsBoston , MA (July 5, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP ® companion diagnostics for personalized cancer care, today announced initial resultsRHEA-AIpositive
06/28/23 11:55 AMNasdaq : ALLR low floatAllarity Therapeutics Announces Reverse Stock Split of Common Stock- Common Stock Will Begin Trading on a Post-Split Adjusted Basis on June 2 9 , 2023 Press R elease BOSTON, MA (June 28, 2023) – Allarity Therapeutics, Inc. (NASDAQ: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together withRHEA-AIneutral
06/27/23 6:16 PMNasdaq : ALLR low floatAllarity Therapeutics Announces Clarification of Effective Date for Reverse Stock SplitPress Release BOSTON, MA (June 27, 2023) – Allarity Therapeutics, Inc. (NASDAQ: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP ® companion diagnostics for personalized cancer care, is issuing thisRHEA-AIneutral
06/20/23 4:05 PMNasdaq : ALLR low floatAllarity Therapeutics Announces Adjournment of Special Meeting of StockholdersMeeting adjourned to Friday, June 23 , 2023 at 1 :00 p .m. Eastern Time Press release BOSTON, MA (June 20, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRPRHEA-AIneutral
05/30/23 6:00 AMNasdaq : ALLR low floatFirst Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual MeetingPhase 2 study e valuating the u tility of a DRP ® c ompanion d iagnostic for cisplatin support s its ability to predict drug response in certain breast cancer patients Boston , M A (May 30, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical companyRHEA-AIneutral